The research results, completed in collaboration by many scientists including Lishu Chen, Qinghui Qi, and Xiaoqing Jiang, were published in the groundbreaking journal Cancer Discovery. The report detailed how phosphocreatine (PCr) promotes the growth of glioblastoma (GBM) by stabilizing bromodomain-containing protein 2 (BRD2). This discovery provid...
In the current field of tumor treatment, precision medicine continues to be a research hotspot and development trend. With the advancement of science and technology, we have begun to more accurately understand the characteristics of tumor cells and their dependencies for survival, in hopes of finding new therapeutic targets. Particularly, strategie...
The Role of IL-33 in Promoting Tumor Growth in Pancreatic Cancer Tissue and its Potential as a Therapeutic Target Background Introduction Pancreatic Cancer (PDA) is one of the most lethal malignancies worldwide, characterized by rapid clinical progression and poor treatment responses, with a five-year survival rate of only 13%. In the United States...
ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer Academic Background and Research Motivation Existing research evidence suggests that cancer cell lineage plasticity and epigenetic reprogramming enable them to evade lineage-dependent targeted therapy by adopting lineage plasticity. Howev...
The Costimulatory Role of CD28 Enhances the Function of CAR-NK Cells through the LCK/CD3ζ/ZAP70 Signaling Axis Research Background and Objective Chimeric Antigen Receptor (CAR) T-cell therapy has shown significant effects in treating certain advanced cancer patients. However, CAR-T cell therapy has many limitations, such as high cost, complex prepa...
Mechanisms of Resistance to Carcinogenic KRAS Inhibition in Pancreatic Cancer Background Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal disease. Most patients are diagnosed at an advanced stage and typically die within 12 months, primarily due to limited treatment options and poor response to standard chemotherapy. KRAS is the most crit...